CL2018003132A1 - Inhibidores de la arginasa y sus aplicaciones terapéuticas. - Google Patents

Inhibidores de la arginasa y sus aplicaciones terapéuticas.

Info

Publication number
CL2018003132A1
CL2018003132A1 CL2018003132A CL2018003132A CL2018003132A1 CL 2018003132 A1 CL2018003132 A1 CL 2018003132A1 CL 2018003132 A CL2018003132 A CL 2018003132A CL 2018003132 A CL2018003132 A CL 2018003132A CL 2018003132 A1 CL2018003132 A1 CL 2018003132A1
Authority
CL
Chile
Prior art keywords
arginase
therapeutic applications
arginase inhibitors
convention
inhibitors
Prior art date
Application number
CL2018003132A
Other languages
English (en)
Inventor
Roman Blaszczyk
Julita Nowicka
Bartlomiej Borek
Joanna Brzezinska
Anna Gzik
Marek Dziegielewski
Adam Golebiowski
Karol Jedrzejczak
Krzysztof Matyszewski
Jacek Olczak
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of CL2018003132A1 publication Critical patent/CL2018003132A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS TERAPÉUTICOS DE MOLÉCULAS PEQUEÑAS QUE SON POTENTES INHIBIDORES DE LA ACTIVIDAD DE LA ARGINASA 1 Y ARGINASA 2. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS Y MÉTODOS PARA USAR LOS COMPUESTOS PARA TRATAR O PREVENIR UNA ENFERMEDAD O AFECCIÓN ASOCIADA CON LA ACTIVIDAD DE LA ARGINASA.
CL2018003132A 2016-05-04 2018-11-05 Inhibidores de la arginasa y sus aplicaciones terapéuticas. CL2018003132A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10

Publications (1)

Publication Number Publication Date
CL2018003132A1 true CL2018003132A1 (es) 2019-02-22

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003132A CL2018003132A1 (es) 2016-05-04 2018-11-05 Inhibidores de la arginasa y sus aplicaciones terapéuticas.

Country Status (24)

Country Link
US (3) US10391077B2 (es)
EP (1) EP3452485B1 (es)
JP (1) JP6971477B2 (es)
KR (1) KR102374788B1 (es)
CN (1) CN109415387B (es)
AU (1) AU2017259887B2 (es)
BR (1) BR112018072545B1 (es)
CA (1) CA3022482A1 (es)
CL (1) CL2018003132A1 (es)
CO (1) CO2018013077A2 (es)
DK (1) DK3452485T3 (es)
ES (1) ES2834065T3 (es)
HR (1) HRP20201821T1 (es)
HU (1) HUE052468T2 (es)
IL (1) IL262387B (es)
LT (1) LT3452485T (es)
MX (1) MX2018013387A (es)
PE (1) PE20181924A1 (es)
PH (1) PH12018501976A1 (es)
PL (2) PL417066A1 (es)
SA (1) SA518400356B1 (es)
SG (1) SG11201807974QA (es)
SI (1) SI3452485T1 (es)
WO (1) WO2017191130A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3719024A1 (en) 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CN108271371B (zh) 2015-10-30 2021-02-09 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CN111712302B (zh) 2018-02-17 2023-09-19 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CR20200445A (es) * 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
WO2019177873A1 (en) * 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3774843B1 (en) 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
US20220056051A1 (en) * 2018-12-18 2022-02-24 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme Llc ARGINASE INHIBITORS AND METHODS OF USE
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
CA2749853C (en) 2009-01-26 2018-08-21 Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
EP3719024A1 (en) 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
CN104857005B (zh) 2010-12-31 2019-04-26 阿斯利康公司 精氨酸酶抑制剂及其使用方法
BR112014009415B1 (pt) 2011-10-19 2021-11-23 Mars, Incorporated Composição farmacêutica, composto inbidor de arginase e seus usos
WO2013158262A1 (en) * 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
EA035790B1 (ru) 2012-07-13 2020-08-11 Янссен Сайенсиз Айрлэнд Юси Макроциклические пурины для лечения вирусных инфекций
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108271371B (zh) 2015-10-30 2021-02-09 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2018089490A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
CN111902532A (zh) 2018-01-28 2020-11-06 日内瓦大学 用于癌症治疗的精氨酸酶抑制

Also Published As

Publication number Publication date
US20170319536A1 (en) 2017-11-09
MX2018013387A (es) 2019-02-28
HUE052468T2 (hu) 2021-04-28
JP2019518726A (ja) 2019-07-04
PE20181924A1 (es) 2018-12-11
BR112018072545B1 (pt) 2022-08-23
WO2017191130A4 (en) 2018-03-01
IL262387B (en) 2021-10-31
US10912755B2 (en) 2021-02-09
CN109415387A (zh) 2019-03-01
US20210260019A1 (en) 2021-08-26
BR112018072545A2 (pt) 2019-06-25
ES2834065T3 (es) 2021-06-16
US10391077B2 (en) 2019-08-27
EP3452485A2 (en) 2019-03-13
HRP20201821T1 (hr) 2021-04-16
CO2018013077A2 (es) 2019-04-30
AU2017259887A1 (en) 2018-09-27
IL262387A (en) 2018-12-31
WO2017191130A3 (en) 2017-12-14
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
KR20190015250A (ko) 2019-02-13
DK3452485T3 (da) 2020-11-09
EP3452485B1 (en) 2020-09-09
PL3452485T3 (pl) 2021-04-19
PH12018501976A1 (en) 2019-07-01
CA3022482A1 (en) 2017-11-09
PL417066A1 (pl) 2017-11-06
AU2017259887B2 (en) 2022-03-17
JP6971477B2 (ja) 2021-11-24
CN109415387B (zh) 2021-08-27
SG11201807974QA (en) 2018-10-30
LT3452485T (lt) 2020-12-28
US20190365701A1 (en) 2019-12-05
WO2017191130A2 (en) 2017-11-09
SI3452485T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
CL2018003132A1 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
CL2018002928A1 (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
BR112019012343A2 (pt) anticorpos il-11ra
BR112019012342A2 (pt) anticorpos il-11
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
CL2016003261A1 (es) Formulación que comprende un profármaco de gemcitabina
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
CY1120095T1 (el) Αναστολεις της erk και μεθοδοι χρησης
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).